
Alterity Therapeutics Limited ATHE
$ 3.45
0.26%
Annual report 2022
added 08-31-2022
Alterity Therapeutics Limited Total Assets 2011-2026 | ATHE
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Alterity Therapeutics Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 41.4 M | 33.6 M | 9.91 M | 19.9 M | 18.7 M | 25.3 M | 33.7 M | 41.8 M | 41.6 M | 17.1 M | 7.34 M | 9.01 M |
All numbers in AUD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 41.8 M | 7.34 M | 24.9 M |
Quarterly Total Assets Alterity Therapeutics Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 41.4 M | - | 44.9 M | - | 33.6 M | - | 37.4 M | - | 9.91 M | - | - | - | 19.9 M | - | - | - | 18.7 M | - | - | - | 25.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in AUD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 44.9 M | 9.91 M | 28.9 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M | ||
|
Alector
ALEC
|
293 M | $ 2.13 | -12.55 % | $ 219 M | ||
|
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | ||
|
BioCardia
BCDA
|
2.99 M | $ 1.37 | 6.2 % | $ 29 M | ||
|
Black Diamond Therapeutics
BDTX
|
123 M | $ 2.4 | -2.83 % | $ 132 M | ||
|
BioLineRx Ltd.
BLRX
|
38.9 M | $ 2.8 | -1.06 % | $ 908 M | ||
|
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | ||
|
BioXcel Therapeutics
BTAI
|
38.3 M | $ 1.64 | -1.8 % | $ 4.16 M | ||
|
AgeX Therapeutics
AGE
|
12 M | - | -10.17 % | $ 12.2 K | ||
|
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | ||
|
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | ||
|
BeyondSpring
BYSI
|
34.3 M | $ 1.44 | 6.3 % | $ 58.1 M | ||
|
Cabaletta Bio
CABA
|
254 M | $ 3.34 | 0.6 % | $ 3.9 M | ||
|
AbCellera Biologics
ABCL
|
1.36 B | $ 3.7 | 2.49 % | $ 1.11 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M | ||
|
Codexis
CDXS
|
149 M | $ 1.05 | 3.47 % | $ 77.1 M | ||
|
Cerus Corporation
CERS
|
201 M | $ 2.6 | 1.56 % | $ 480 M | ||
|
Certara
CERT
|
1.56 B | $ 7.17 | 1.27 % | $ 1.15 B | ||
|
Cullinan Management
CGEM
|
622 M | $ 15.91 | 2.65 % | $ 931 M | ||
|
Compugen Ltd.
CGEN
|
115 M | $ 2.28 | 25.97 % | $ 204 M | ||
|
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | ||
|
Coherus BioSciences
CHRS
|
630 M | $ 1.66 | -0.9 % | $ 156 M | ||
|
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - | ||
|
AIkido Pharma
AIKI
|
47.1 M | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | ||
|
Cellectis S.A.
CLLS
|
384 M | $ 3.88 | - | $ 116 M | ||
|
Allena Pharmaceuticals
ALNA
|
34.8 M | - | 3.16 % | $ 1.9 M | ||
|
Aileron Therapeutics
ALRN
|
62.2 M | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
119 M | - | 4.14 % | $ 49.1 M | ||
|
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | ||
|
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M | ||
|
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | ||
|
CNS Pharmaceuticals
CNSP
|
8.7 M | $ 3.1 | -0.44 % | $ 1.18 M | ||
|
Aravive
ARAV
|
62.2 M | - | -13.39 % | $ 1.45 M | ||
|
Cocrystal Pharma
COCP
|
13.5 M | $ 1.02 | -0.97 % | $ 10.4 M | ||
|
Aptose Biosciences
APTO
|
10.1 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
66.7 M | - | -39.0 % | $ 4.57 M | ||
|
Collegium Pharmaceutical
COLL
|
1.66 B | $ 42.0 | 0.79 % | $ 1.33 B | ||
|
Corcept Therapeutics Incorporated
CORT
|
837 M | $ 35.61 | -0.25 % | $ 3.7 B | ||
|
Athira Pharma
ATHA
|
58.8 M | - | - | $ 269 M | ||
|
Aridis Pharmaceuticals
ARDS
|
14.7 M | - | 17.91 % | $ 11.1 M |